Strattera

Strattera, a drug for attention-deficit and hyperactivity disorders, generated revenue of $98.3 million in 4Q17, representing a ~60.0% fall from the $243.2 million seen in 4Q16. The decline was due to lower US sales and partially offset by strong international sales. US sales fell ~95.0% to $8.0 million, while ...

“Strattera Drug Insights, 2018-2020” Market report highlights the Drug marketed details and the Global API Manufacturers details across the globe along with the location. The report covers the patents information and market exclusivity data, route of synthesis, market competition, and API manufacturers by ...

He told the court he had also been taking a drug called Strattera at the time of the bomb threats, despite not having a prescription for it. Strattera is commonly used to treat attention deficit hyperactivity disorder (ADHD). Saadi said he used the drug as a stimulant, taking it whenever he needed a concentration ...

Strattera Market Drug report 2018 pin-point about Drug details and the Global API Manufacturers facts across the globe along with the location of Strattera Industry. The report covers the patents information and market exclusivity data, route of synthesis, market competition, and API manufacturers by country ...

omeone high up in Eli Lilly and Company must be a “South Park” fan. When the company failed to ensure that the patents it filed on two blockbuster drugs, Zyprexa and Strattera, complied with Canadian law, it decided to “Blame Canada” 1 rather than take responsibility for its error. The company sued the ...

Strattera is the brand name for atomoxetine, a selective norepinephrine reuptake inhibitor that was one of the first nonstimulant medications available for the treatment of ADHD. Since the drug's patent expired in May, four companies — Apotex Inc., Teva Pharmaceuticals USA Inc., Aurobindo Pharma ...

The U.S. Food and Drug Administration today approved the first generic versions of Strattera (atomoxetine) to treat attention-deficit/hyperactivity disorder (ADHD) in pediatric and adult patients. Apotex Inc., Teva Pharmaceuticals USA Inc., Aurobindo Pharma Limited and Glenmark Pharmaceuticals Limited ...

Strattera is a non-stimulant medication used to treat symptoms of attention deficit hyperactivity disorder (ADHD or ADD) including distractibility, impulsivity, and hyperactivity in children, teens, and adults with ADHD. Strattera has long been advertised as the first non-stimulant medication for ADHD, however doctors also ...

... dexmethylphenidate hydrochloride (Focalin), dextroamphetamine sulfate (Dexedrine), lisdexamfetamine dimesylate (Vyvanse), methamphetamine hydrochloride (Desoxyn), methylphenidate, and methylphenidate hydrochloride. Also included was atomoxetine hydrochloride (Strattera), a non-stimulant ...

A month has gone by since the last earnings report for Eli Lilly and Company LLY . Shares have lost about 7.2% in the past month, underperforming the market. Will the recent negative trend continue leading up to its next earnings release, or is LLY due for a breakout? Before we dive into how investors and ...